Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Short-term follow-up results of ultra-low-dose radiotherapy for indolent B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMin LiHWHao Wang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows a 35.7% complete response in patients with indolent B-cell lymphoma, indicating effective treatment outcomes.

Key Points

  • Complete response observed in 35.7% of patients with indolent B-cell lymphoma treated with ultra-low-dose radiotherapy.
  • One-year progression-free survival rate reached 83.9%, suggesting lasting effects post-treatment.
  • Observational analysis of 14 patients with follicular and mucosa-associated lymphoid tissue lymphomas treated with low-dose therapy.
  • Results highlight the potential of ultra-low-dose radiotherapy in reducing treatment-related toxicities while maintaining efficacy.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da38https://doi.org/10.1182/blood-2025-7113
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas2025 · 1 citations
  2. 2Clinical Outcomes and Safety of Ultra-Low-Dose Radiotherapy for Ocular Adnexal Lymphoma: A Systematic Review2025 · 4 citations
  3. 3Locally advanced breast cancer: primary ultra-hypofractionated radiotherapy for inoperable or frail patients2025
  4. 4Radiotherapy for benign conditions: management of persistent lymphorrea2025
  5. 5Impact of extranodal involvement in stage I aggressive B-cell lymphoma in the rituximab era: An individual patient data meta-analysis of two Phase III dshnhl/GLA trials2025